著者
Aya Ishizuka Mina Chiba Hiroyasu Iso Yasushi Katsuma
出版者
National Center for Global Health and Medicine
雑誌
GHM Open (ISSN:2436293X)
巻号頁・発行日
pp.2021.01006, (Released:2021-09-29)
参考文献数
50

The Group of 20 (G20) Osaka Summit in 2019 was a large step forward for global health diplomacy to build consensus on universal health coverage (UHC). To strengthen multi-stakeholder UHC partnership, Japan involved the research and policy advice network for G20 (Think 20: T20), civil society (Civil 20: C20), private initiatives of medical professional groups (H20), and the pharmaceutical sector. We attempted to identify UHC-related issues addressed and left unaddressed at the G20 Osaka, to bring lessons for future G20. We reviewed the G20 Osaka Leaders' Declaration, policy-related statements, and voices of the relevant G20 engagement groups and sectors. In July 2019, after the G20 Osaka Leaders' Summit, we organized an expert meeting convening Japan-based UHC-related key global health stakeholders. This review provides record of main findings presented in form of classifying the voices expressed in the meeting by UHC-related topics, and definitional ranges of UHC summarized. The T20, H20, and the pharmaceutical sector noted during our expert meeting that the ministerial-level health-finance collaboration was one of the key agendas suggested at the G20. T20 and C20 called for a recognition of health needs of refugees, migrants and other vulnerable groups in achieving UHC. Sexual and reproductive health and rights (SRHR) with a human rights-based approach through UHC was raised by the C20 as an issue unaddressed in G20 Osaka. Variation in operative purposes between global health stakeholders led to a definitional difference in the scope of UHC. The definitional difference could delay progress of UHC attainment. Addressing migrant and refugee health and SRHR within the context of UHC is further needed. Understanding perspectives of various stakeholders will become increasingly important to well-coordinate multi-actor cooperation with adequate social responsibility and transparency in UHC achievement and public-private partnership. In future G20, for UHC in the COVID-19 pandemic and post-pandemic worlds there is need of i) ensuring an integrated yet comprehensive multi-stakeholder approach towards UHC; ii) incorporating important dimensions such as the marginalized population and gender; and iii) ensuring adequate investments toward health information systems and governance to track health data for the vulnerable population and gender-responsive financing.
著者
M. Ibrahim Hossain Esha Binte Shahriar Anamika Sarker Nafisa Lubna Mehjabeen Haque Md. Ibrahim Khalil
出版者
National Center for Global Health and Medicine
雑誌
GHM Open (ISSN:2436293X)
巻号頁・発行日
vol.1, no.1, pp.12-19, 2021-08-29 (Released:2021-09-01)
参考文献数
68

The world is now facing one of the most devastating public health concern where the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading all over the world initiating from Wuhan, China, started from December, 2019. The World Health Organization (WHO) already announced the situation as pandemic all over the world. According to the webpage of WHO, this SARS-CoV-2 has been spreading all over the world (223 countries, areas or territories) with 126,890,643 confirmed cases of coronavirus disease 2019 (COVID-19) and 2,778,619 confirmed deaths (as of March 30, 2021). Accumulated published documents indicate that the SARS-CoV-2 virus primarily affects the lungs causing hypoxia, which is the leading cause of death. There are many reports describing that with the progress of this disease, many other organs (such as heart, kidney, liver, brain) of the affected person start to malfunction. Though SARS-CoV-2 uses the cell surface receptor angiotensin-converting enzyme 2 (ACE-2) expressed by lungs, cardiovascular system, and kidneys but it is still not clear except for lungs that all these other organs are directly affected by this virus or not. Therefore, the aim of this review is to gather informations about affected/damaged organs or tissues and consequences of this damage in COVID-19 patients.
著者
Ryotaro Bouchi Kazuo Izumi Hiroshi Ohtsu Kengo Miyo Shigeho Tanaka Noriko Satoh-Asahara Kazuo Hara Masato Odawara Yoshiki Kusunoki Hidenori Koyama Takeshi Onoue Hiroshi Arima Kazuyo Tsushita Hirotaka Watada Takashi Kadowaki Kohjiro Ueki
出版者
National Center for Global Health and Medicine
雑誌
GHM Open (ISSN:2436293X)
巻号頁・発行日
vol.1, no.1, pp.3-11, 2021-08-29 (Released:2021-09-01)
参考文献数
30

The use of the Internet-of-Things has improved glycemic control in individuals with diabetes in several small-scale studies with a short follow-up period. This large-scale randomized controlled trial investigates whether a smartphone-based self-management support system prevents the worsening of glycemic control in individuals with type 2 diabetes. Individuals with type 2 diabetes (age range 20-74 years; n = 2,000) will be recruited, enrolled, and randomly assigned to two groups: the intensive therapy group and the conventional therapy group. Participants in the intensive therapy group will be supervised to use an automated Internet-of-Things system that demonstrates a summary of lifelogging data (e.g., weight, blood pressure, and daily activities) obtained from each measurement device and will receive feedback messages via smartphone applications to encourage them to increase their physical activity and to monitor weight and blood pressure. Participants in the conventional therapy group are allowed to use the same measurement devices as part of the routine diabetes care but without the Internet-of-Things system. The primary endpoint is the between-group difference in HbA1c levels from baseline to 52 weeks. This randomized controlled study will test the hypothesis that an Internet-of-Things-based self-monitoring system could effectively prevent the worsening of diabetes in individuals with type 2 diabetes. The expected results of the study should facilitate the development of novel strategies for both diabetes treatment and social health.
著者
Norihiro Kokudo
出版者
National Center for Global Health and Medicine
雑誌
GHM Open (ISSN:2436293X)
巻号頁・発行日
vol.1, no.1, pp.1-2, 2021-08-29 (Released:2021-09-01)
参考文献数
7

To generate high-quality evidence and serve as a platform for interdisciplinary communication regarding challenging issues in global health and medicine, we are launching a new open-access multispecialty journal — GHM Open (www.ghmopen.com) – with the goal of creating a network to share global health information and findings from basic science and clinical science for use in practice. GHM Open will be an inclusive and global journal; the diversity of our editorial board, authors, and reviewers will allow us to showcase rich and wide-ranging content, making it ever more relevant to researchers and clinicians around the world. The journal prioritizes specialized research with wider general relevance that will influence clinical care, global health, public health, medical education, and the direction of future research. We aim to be relevant, accessible, and enjoyable, not only to researchers but also to global health and medical care providers. We sincerely look forward to having you join us as a reader, author, reviewer, or editorial board member to address challenging issues in global health and medicine.
著者
Yukari Isaka Ai Hori Takahiro Tabuchi Sumiyo Okawa Masao Ichikawa
出版者
National Center for Global Health and Medicine
雑誌
GHM Open (ISSN:2436293X)
巻号頁・発行日
vol.1, no.1, pp.38-39, 2021-08-29 (Released:2021-09-01)
参考文献数
6
被引用文献数
1

Home-visit services are provided to families with newborns as means of parenting support. These services potentially are playing major roles during the coronavirus disease 2019 (COVID-19) pandemic, where people have been socially isolated. However, the pandemic has deterred the use of this service to some extent. From the Japan "COVID-19 and Society" Internet Survey, we identified that 15% of the survey respondents who delivered between January 2020 and October 2020 refused home visit services. The proportion of the services used during the pandemic (85%) was lower than those used before the pandemic (95%). Home-visit services provide a unique opportunity for public health nurses to assess the risk of postpartum depression and child maltreatment in the family; thus, families with newborns should be instructed to receive home-visit services as well as child immunization and health checkups, despite the continuation of the pandemic.
著者
Akihiko Nishikimi Masayo Kojima Ken Watanabe Atsushi Watanabe Mikako Yasuoka Hironori Oshima Haruhiko Tokuda Shumpei Niida
出版者
National Center for Global Health and Medicine
雑誌
GHM Open (ISSN:2436293X)
巻号頁・発行日
vol.1, no.1, pp.40-42, 2021-08-29 (Released:2021-09-01)
参考文献数
9
被引用文献数
2

To achieve effective prevention and control strategies for COVID-19, regular survey of seroprevalence of antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is essential. Using four serological tests, we examined the residual sera collected in an annual medical checkup of the staff members of the National Center for Geriatrics and Gerontology in Aichi Prefecture, Central Japan in June 2020. Of the 631 samples, two were positive for anti-SARS-CoV-2 antibodies in at least two tests, showing a seroprevalence of 0.32%. Four subjects showed positive results in only one test. All individuals were asymptomatic and had not been in close contact with patients diagnosed with COVID-19. Multiple antibody tests could be used to assess the prevalence of SARS-CoV-2 infection including individuals without COVID-19 symptoms.
著者
Yudong Wang Gregory Cheng George Lau
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2021.01075, (Released:2021-08-13)
参考文献数
40

With the introduction of effective directly acting antiviral agents (DAAs) therapy, control and elimination of hepatitis C virus (HCV) infection is becoming a feasible goal. In Hong Kong, HCV prevalence in general population is 0.3%-0.5% over the past decades. However, like other high-income areas/countries, high prevalence of HCV infection has been found in several population groups, such as people who inject drugs (PWID), patients undergoing dialysis, and human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS) patients. Based on the epidemiological study using data retrieved from the Hong Kong HCV Registry from January 2005 to March 2017, the estimated territory-wide diagnosis rate and treatment rate of HCV infection were only 50.9% and 12.4%, respectively. Although these rates was comparable to many developed countries/areas, the performances remained substantially below 90% and 80%, the 2030 targets proposed by World Health Organization (WHO). In recognition of the challenges, the Hong Kong Government set up the Steering Committee on Prevention and Control of Viral Hepatitis (SCVH) which formulated the Hong Kong Viral Hepatitis Action Plan 2020-2024. The Action Plan adopts four key strategies, as described in the WHO framework for global action, namely, awareness, surveillance, prevention and treatment. With the effective implementation of the Action Plan, especially in targeted screening of high-risk populations and more generalized use of the highly efficacious DAAs for all diagnosed HCV subjects, the goals of reducing HCV transmission and HCV-related morbidity and mortality can be achieved in Hong Kong by 2030.
著者
Ko Ko Tomoyuki Akita Masahiro Satake Junko Tanaka
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2021.01069, (Released:2021-08-13)
参考文献数
33
被引用文献数
4

Although HCV infection was the main cause of HCC in Japan contributing 70% over two decades after its first cloning in 1989, it was markedly decreased to 49% in 2013 and expected to decrease continuously. Based on blood donor national database, the new incident cases were 0.4/100,000 person-years, the prevalence was 0.13% and the total number was 890,902-1,302,179 in 2015. Establishment of blood donor screening with anti-HCV measurement and nucleic acid test introduced by Japanese Red Cross as pioneer, high-level medical and surgical care, and the government's policy under the Basic Act on Hepatitis Control have changed its epidemiology and outbreak trend and also enforced the disruption of potential transmission cascades. HCV prevalence among the younger generation was extremely low in all regions, and the predominant age for HCC has shifted to over 60 years old population. Considering such changes, HCV induced HCC occurrence is supposed to be ultimately suppressed in the near future. However, taking into account society changes, regulating intravenous drugs users and monitoring high-risk groups such as tattoos, and men who have sex with men are indeed required in Japan. Understanding the epidemiological changes in HCV is important in assigning, modifying, and designating effective response systems. Selective or national action plans, strategic approaches, and cooperation between government sectors have a positive impact on HCV prevention and control. A dramatic decrease in total number of HCV carriers, increase in number of people treated with highly effective DAA, and subsequent high SVR indicates Japan might achieve WHO's target of HCV elimination by 2030.
著者
Po-Lin Chan Linh-Vi Le Naoko Ishikawa Philippa Easterbrook
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2021.01065, (Released:2021-08-13)
参考文献数
58
被引用文献数
14

Chronic hepatitis C (HCV) infection is a major global public health threat and in 2019 there were an estimated 58 million infected globally and 290,000 deaths. Elimination of viral hepatitis B/C as a public health threat by 2030 is defined as a 90% incidence reduction and a 65% mortality reduction. The Western Pacific region is one of the most affected regions with 10 million people living with HCV, one-fifth of the global burden. We review progress towards HCV elimination in the Western Pacific region since 2015. Key developments in the region, which comprises of 37 high-and-middle-income countries, include the following: 20 countries have national hepatitis action plans, 19 have conducted recent disease burden and investment cases, 10 have scaled-up hepatitis services at primary health care level, and in 11 countries, domestic financing including social health insurance support DAA costs. We highlight six countries' experience in navigating the path towards HCV elimination: Cambodia, China, Malaysia, Mongolia, Philippines, and Viet Nam. Future initiatives to accelerate elimination are expanding access to community-based testing using HCV point-of-care tests among at-risk and general populations; adopting decentralized and integrated HCV one-stop services at harm reduction sites, detention settings and primary care; expanding treatment to include children and adolescents; address stigma and discrimination; and ensuring sustainable financing through domestic resources to scale-up testing, treatment and prevention. The COVID-19 pandemic has a significant impact on hepatitis response across the region on community and facility-based testing, treatment initiation, monitoring and cancer screening, which is projected to delay elimination goals.
著者
Sadatoshi Matsuoka Yoshito Kawakatsu Sumiko Koga Nurian Ayeola Veronica Iwayemi Chika Saito Hitoshi Murakami Masahiko Hachiya
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
vol.2, no.3, pp.184-189, 2020-06-30 (Released:2020-07-04)
参考文献数
21

Lagos State, Nigeria, Africa’s largest city with an estimaed 21 million population, continues to face challenges in its attempts to reduce maternal mortality (555 deaths per 100,000 live births) and deaths of children under five (59 per 1,000 live births). These deaths are more common among women and children living in poverty, many of whom rarely utilize health services. This paper describes the trend in the use of maternal, neonatal and child health (MNCH) services in the State in the past decade and shows barriers to the use of the services. Significant improvement in the coverage of the services were not observed. We identified the following five types of barriers to the use of MNCH services: i) financial barriers, ii) physical barriers, iii) cognitive barriers, iv) organizational barriers, and v) psychological and socio-cultural barriers. To address these interrelated barriers, the Lagos State Ministry of Health should prioritize regular outreach health services including health promotion, and realize the current initiative for massive recruitment of health personnel and appropriate deployment of them.
著者
Shuji Kubota Hisao Hara Yukio Hiroi
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2021.01024, (Released:2021-07-03)
参考文献数
98
被引用文献数
8

The prognosis has improved remarkably in recent years with the development of cancer treatment. With the increase in the number of cancer survivors, complications of cardiovascular disease have become a problem. Therefore, the field of onco-cardiology has been attracting attention. The field of onco-cardiology covers a wide range of areas. In the past, cardiac dysfunction caused by cardiotoxic drug therapies such as doxorubicin (Adriamycin) was the most common cause of cardiac dysfunction, but nowadays, cardiovascular complications caused by aging cancer survivors, atherosclerotic disease in cardiovascular risk carriers, thromboembolism, and new drugs (e.g., myocarditis caused by immune checkpoint inhibitors and hypertension caused by angiogenesis) are becoming more common. In this review, we summarize the latest findings of cardiotoxicity of cancer therapy, appropriate treatment and prevention, and cardiovascular complications of novel chemotherapy, which will increase in demand in the near future.
著者
Rubuna Sato Masahiro Ishikane Noriko Kinoshita Tetsuya Suzuki Takato Nakamoto Kayoko Hayakawa Norifumi Bekki Hisao Hara Norio Ohmagari
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
vol.2, no.3, pp.190-192, 2020-06-30 (Released:2020-07-04)
参考文献数
13
被引用文献数
1 14

Hypercoagulation and anticoagulation treatment have become new challenges in coronavirus disease 2019 (COVID-19) patients during the COVID-19 pandemic. We herein suggest an algorithm for an anticoagulation treatment with unfractionated heparin in moderate to severe COVID-19 cases in Japan, and report a case of COVID-19 pneumonia with anticoagulation treatment. Although several promising drugs for COVID-19 are being tested in clinical trials, definitive treatments have not yet been established. In this report, we demaonstrate that anticoagulation treatment with unfractionated heparin has the possibility of becoming at least a supportive treatment for COVID-19 patients.
著者
Norihiro Kokudo Haruhito Sugiyama
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
vol.3, no.2, pp.56-59, 2021-04-30 (Released:2021-05-08)
参考文献数
8
被引用文献数
29

The rapid global spread of the COVID-19 pandemic has posed a significant challenge to various countries in terms of the capacity of hospitals to admit and care for patients during the crisis. To estimate hospital capacity during the COVID-19 pandemic, clinicians working in tertiary hospitals around the world were surveyed regarding available COVID-19 hospital statistics. Data were obtained from 8 tertiary centers in 8 countries including the United States, United Kingdom, Switzerland, Turkey, Singapore, India, Pakistan, and Japan. The correlation between the number of patients with COVID-19 per 1 million population vs. the maximum number of inpatients with COVID-19 in a representative tertiary hospital in each country was determined, as was the correlation between COVID-19 deaths per 1 million population vs. the maximum number of patients with COVID-19 in the intensive care unit (ICU). What was noteworthy was that none of the 8 hospitals reduced emergency room (ER) activity even at the peak of the pandemic although treatment of patients without COVID-19 decreased by 0-70% depending on the extent of the epidemic. Although various measures are being actively implemented to slow the spread of the virus and reduce the strain on the health care system, the reality is that there are still a significant number of hospitals at risk of being overloaded in the event of a future surge in cases.
著者
Shigeko Yashiro Takashi Ueta Satoshi Kutsuna Tatsuya Okamoto Miyuki Nagahara Norio Ohmagari
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2020.01091, (Released:2020-12-14)
参考文献数
10
被引用文献数
3

Ocular complications of coronavirus disease 2019 (COVID-19) do not essentially cause serious visual loss. However, due to the characteristics of this disease, delays in diagnosis and treatment in hospitalized patients may leave them with serious visual impairment. If conjunctivitis is suspected, ophthalmological follow-up is needless because it is expected spontaneous healing. Diplopia is often complicated for extra-ocular neurological findings and need neurological consults. Ophthalmologists should be consulted for ocular surface disease, high intraocular pressure, and ocular inflammation that may cause visual loss if patients complain of blurred vision, visual loss, and ocular pain. The problem is unconscious patients with risk of developing high intraocular pressure or keratitis. An ophthalmologist should be consulted as soon as possible if eye redness or pupil abnormalities appear in these patients. We developed a flowchart for ophthalmic consultations in hospitalized patients with COVID-19, for facilities where an ophthalmologist is not always present, and for third or fourth waves or, a pandemic of another infectious disease.
著者
Eloisa Franchi Matteo Donadon Guido Torzilli
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2020.01013, (Released:2020-09-04)
参考文献数
59
被引用文献数
8

The positive relationship between volume and outcome in hepatobiliary surgery has been demonstrated for many years. As for other complex surgical procedures, both improved short- and long-term outcomes have been associated with a higher volume of procedures. However, whether the centralization of complex hepatobiliary procedures makes full sense because it should be associated with higher quality of care, as reported in the literature, precise criteria on what to centralize, where to centralize, and who should be entitled to perform complex procedures are still missing. Indeed, despite the generalized consensus on centralization in hepatobiliary surgery, this topic remains very complex because many determinants are involved in such a centralization process, of which some of them cannot be easily controlled. In the context of different health systems worldwide, such as national health systems and private insurance, there are different stakeholders that demand different needs: politicians, patients, surgeons, institutions and medical associations do not always have the same needs. Starting from a review of the literature on centralization in hepatobiliary surgery, we will propose some guidelines that, while not data-driven due to low evidence in the literature, will be based on good clinical practice.
著者
Guido Torzilli Jacopo Galvanin Luca Viganò Matteo Donadon Marco Montorsi
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2020.01039, (Released:2020-05-28)
参考文献数
13
被引用文献数
3

After the initial description of COVID-19 in Wuhan, China, Italy was hit first in Europe and the impact has been rapidly enlarging. In early April 2020, at the epidemic peak, there were more than 33,000 patients hospitalized including more than 4,000 in Intensive Care Units (ICU). On May 15, the confirmed cases in Italy approached 224,000 patients (5th highest number worldwide), with more than 31,000 deaths (3rd highest number worldwide). Non-urgent, non-cancer procedures were stopped to reallocate nurses and anesthetists to face the COVID-19 emergency. The timeline of the progressive involvement by COVID-19 patients of 36 hospitals referrals for surgical oncology in Italy was shown in this article. Only emergency, and elective oncological procedures were allowed with obvious limitations in terms of numbers of operable cases. Criteria for prioritizing oncologic patients waiting for surgery were released by each region, mainly issuing main factors for decision making, biological aggressiveness or symptomatic disease, the interval from the latest treatment, and the risk of un-resectability if delayed. However, the lack of facilities mostly influenced the decision or not to proceed. The risk of operating on oncological patients with ongoing SARS-CoV-2 syndrome is real, and a preoperative flowchart for ruling out this occurrence has been promoted. In our center, the day before surgery, chest CT and swab testing have been introduced, and a similar behavior has been recommended prior to patients' discharge. The care of patients addressed for surgical oncology should be featured by dedicated paths to secure proper and prompt disease management.